Matthias Aizenberg

Clinical Outcome Assessments (COAs) play a pivotal role in the drug development process. These tools, which measure the impact of a treatment on patients' health status, encompass several types: Patient-Reported Outcomes (PROs), Clinician-Reported Outcomes (ClinROs), Observer-Reported Outcomes

Catalent, a prominent contract development and manufacturing organization (CDMO), has announced the divestment of its Somerset, New Jersey, oral solids development and small-scale manufacturing facility to Ardena, a Belgian CDMO. This transaction marks Ardena's entry into the U.S. market and

The pharmaceutical industry is on the cusp of transformative changes over the next decade. Driven by new legislation and technological advancements, companies are rethinking traditional practices. The Biosecure Act, soon to be enacted in the US, and the rise of AI and automation, are key drivers of

The realm of biotechnology and digital health is increasingly characterized by burgeoning partnerships between pharmaceutical giants and innovative start-ups. These alliances are more than just trendy business moves; they represent a technological and strategic pivot aimed at advancing research,

The Biosecure Act, proposed by the U.S. government last year, aims to safeguard national security by regulating how genetic and biological data are handled, specifically targeting entities linked to adversarial governments like China. With a focus on preventing U.S. federal agencies from engaging

The Global Mammalian Biopharmaceutical Service Market has seen impressive evolution over the years. This article delves into its historical backdrop, current trends, and future projections, providing a comprehensive view for industry professionals. The ongoing influence of technological

The controversy surrounding Cassava Sciences and its experimental Alzheimer's drug, simufilam, has garnered significant attention within the medical and research communities, as well as among regulatory bodies and patient advocacy groups. Allegations of data manipulation and scientific

Biopharmaceutical companies face numerous challenges in the quest to develop and commercialize effective oncology drugs. The intricate journey from Phase 1 trials to market approval often sees only a small fraction of drugs succeeding, and even when they do, understanding how new drug approvals

Thailand's biotechnology sector is undergoing a transformative shift, driven by strategic partnerships, cutting-edge innovations, and robust support for entrepreneurs. The Thailand Center of Excellence for Life Sciences (TCELS) is at the forefront of this transformation, spearheading

The relationship between Big Pharma and AI-focused biotechs is at a crossroads, with implications that could redefine the landscape of drug research and development. For years, the promise of artificial intelligence (AI) has enticed major pharmaceutical companies to collaborate with nimble biotech